- Home
- OABI vs FHTX Comparison
OABI vs FHTX Comparison
Compare OABI & FHTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- OABI
- FHTX
- Stock Information
- Founded
- OABI 2012
- FHTX 2015
- Country
- OABI United States
- FHTX United States
- Employees
- OABI N/A
- FHTX 112
- Industry
- OABI Biotechnology: Pharmaceutical Preparations
- FHTX Medicinal Chemicals and Botanical Products
- Sector
- OABI Health Care
- FHTX Health Care
- Exchange
- OABI Nasdaq
- FHTX Nasdaq
- Market Cap
- OABI 198.2M
- FHTX 271.5M
- IPO Year
- OABI N/A
- FHTX 2020
- Fundamental
- Price
- OABI $2.10
- FHTX $5.01
- Analyst Decision
- OABI Strong Buy
- FHTX Strong Buy
- Analyst Count
- OABI 3
- FHTX 8
- Target Price
- OABI $7.00
- FHTX $12.63
- AVG Volume (30 Days)
- OABI 880.0K
- FHTX 139.1K
- Earning Date
- OABI 08-07-2025
- FHTX 08-07-2025
- Dividend Yield
- OABI N/A
- FHTX N/A
- EPS Growth
- OABI N/A
- FHTX N/A
- EPS
- OABI N/A
- FHTX N/A
- Revenue
- OABI $26,744,000.00
- FHTX $23,504,000.00
- Revenue This Year
- OABI N/A
- FHTX $44.01
- Revenue Next Year
- OABI $45.65
- FHTX $9.45
- P/E Ratio
- OABI N/A
- FHTX N/A
- Revenue Growth
- OABI 27.07
- FHTX N/A
- 52 Week Low
- OABI $1.22
- FHTX $2.95
- 52 Week High
- OABI $4.96
- FHTX $10.25
- Technical
- Relative Strength Index (RSI)
- OABI 72.48
- FHTX 57.60
- Support Level
- OABI $1.79
- FHTX $4.78
- Resistance Level
- OABI $1.73
- FHTX $5.18
- Average True Range (ATR)
- OABI 0.11
- FHTX 0.28
- MACD
- OABI 0.04
- FHTX -0.00
- Stochastic Oscillator
- OABI 93.97
- FHTX 58.33
About OABI OmniAb Inc.
OmniAb Inc offers therapeutic antibody discovery technologies. It focuses on enabling the rapid development of therapeutics by pushing the frontiers of drug discovery technologies. Its technology platform is designed to enable the efficient discovery of high-quality, fully human antibodies for a wide range of diseases. The heart of the OmniAb technology platform is the Biological Intelligence of its proprietary transgenic animals, including OmniRat, OmniMouse, and OmniChicken, that have been genetically modified to generate antibodies with human sequences which are naturally optimized through in vivo affinity maturation.
About FHTX Foghorn Therapeutics Inc.
Foghorn Therapeutics Inc is engaged in the discovery and development of a new class of medicines targeting genetically determined dependencies within the chromatin regulatory system. Its proprietary Gene Traffic Control platform gives an integrated, mechanistic understanding of how the various components of the chromatin regulatory system interact, allowing it to identify, validate, and potentially drug targets within the system. The company is developing FHD-286, a selective, allosteric ATPase inhibitor, and FHD-609, a protein degrader, to treat hematologic cancers and solid tumors.